HCRN GI15-225
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225
Status: Closed to Accrual
- Condition: Hepatocellular carcinoma
- Intervention:
- Drug: Pembrolizumab
- Drug: Y90 radioembolization
- Phase: Pilot study
For full description, see www.clinicaltrials.gov. (Study #NCT03099564).
Read a news release about this trial.
Funding for this study is provided by Merck Sharp & Dohme Corp.
Study Contact: studies@hoosiercancer.org; (317) 921-2050.
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter